Editas

The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.

The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

Editas has paid $1 million to test-drive Adverum's viral vectors in clinical gene editing and $1 million for an option on an exclusive license.

The Massachusetts-based clinical gene editing firm has obtained exclusive rights to use the engineered Cas9 variants developed by one of its co-founders.

The deal sets up a multi-year collaboration on hematopoietic stem cell and T-cell editing with the San Raffaele Telethon Institute for Gene Therapy.

CFFT will support drug discovery and development for cystic fibrosis while Editas will look into both common and uncommon mutations.

Pages

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.